Advertisement
ABT vs MDT
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- Abbott Laboratories (ABT) is a diversified healthcare company spanning medical devices, diagnostics, nutrition, and branded generics, while Medtronic (MDT) is a pure-play medical device leader focused on cardiovascular, neuroscience, medical-surgical, and diabetes therapies.
- Recent market activity has diverged: ABT came under pressure after a fourth-quarter revenue miss and weakness in diagnostics and nutrition, whereas MDT has posted consecutive beats and raised its growth guidance.
- ABT is pursuing a large acquisition of Exact Sciences to enter cancer diagnostics, adding execution risk but also a new growth avenue; MDT is preparing to spin off its high-growth Diabetes business.
- Both companies are dependable dividend growers, with decades of consecutive annual dividend increases.
- Sentiment has shifted more favorably toward MDT in recent weeks, including an upgrade by Goldman Sachs, while ABT trades near its 52-week low.
Introduction
This stock comparison examines two of the world's largest healthcare companies: Abbott Laboratories (ABT) and Medtronic (MDT). Both operate at the intersection of medical technology and chronic disease management, yet their business models, growth profiles, and recent market positioning differ meaningfully. Investors comparing the two are often weighing a diversified healthcare conglomerate against a more focused device maker. The analysis is particularly relevant for traders and long-term investors evaluating relative performance, momentum, and how each company is navigating the current macro environment, including tariff pressures, post-pandemic normalization, and evolving demand in core therapeutic markets.
ABT Overview and Recent Performance
ABT operates through four segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. In recent weeks, the stock has faced notable headwinds. Its latest quarterly report showed adjusted earnings per share (EPS) in line with expectations, but revenue fell short of Wall Street forecasts, driven largely by softer diagnostics demand as COVID-era testing continues to fade and by a decline in the Nutrition segment tied to competitive pressures and the loss of a major U.S. pediatric contract.
The negative reaction pushed shares toward their 52-week low, reflecting investor concern about the durability of top-line growth. Positively, the Medical Devices division remains a bright spot, with strong double-digit growth in areas such as diabetes care, electrophysiology, and heart failure. Management also announced an agreement to acquire Exact Sciences, positioning ABT to enter the fast-growing cancer diagnostics market. While the deal broadens the growth pipeline, it introduces integration and balance-sheet considerations that have tempered near-term enthusiasm.
MDT Overview and Recent Performance
MDT is a focused medical device company whose portfolio spans cardiovascular, neuroscience, medical-surgical, and diabetes therapies. Its recent market activity has been comparatively constructive. The company reported a quarterly revenue and EPS beat, led by strength in its Cardiovascular and Diabetes businesses, and management raised its full-year organic growth guidance to roughly 5.5%.
Investor sentiment has improved in recent weeks, highlighted by an analyst upgrade and several reaffirmed Buy ratings with price targets above the prevailing share price. MDT is also advancing a planned separation of its Diabetes unit, a move management expects to enhance margins and earnings per share over time. The stock offers a dividend yield in the low-3% range and has delivered decades of consecutive dividend increases. While operating-margin performance has been mixed as the company steps up research and development investment, the broader trend has been one of accelerating momentum and a strengthening product cycle.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing automated strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, timeframe, risk profile, and performance statistics. Because market conditions change constantly, not every bot deserves attention at any given moment. The Trending AI Robots section is designed to surface only the most suitable bots for the current environment, helping users identify strategies aligned with prevailing momentum and volatility. Explore the Trending AI Robots page to see which automated approaches are currently leading the market.
Head-to-Head Comparison
The core contrast between ABT and MDT lies in diversification versus focus. ABT spans devices, diagnostics, nutrition, and generics, which historically provides balance but also exposes it to post-pandemic normalization in testing and consumer-driven softness in nutrition. MDT, by contrast, concentrates on medical devices, a category enjoying steadier demand and strong product momentum in cardiac ablation and diabetes.
On growth drivers, ABT is betting on its Exact Sciences acquisition to accelerate diagnostics, while MDT is streamlining via a diabetes spin-off to sharpen its focus and margins. Momentum currently favors MDT, which has beaten estimates and raised guidance, whereas ABT has been re-rated lower after a revenue shortfall. Risk profiles also differ: ABT carries acquisition integration and nutrition-recovery uncertainty, while MDT faces tariff exposure and elevated leverage. In terms of market positioning, MDT trades with a more favorable sentiment backdrop, while ABT appears cheaper relative to its own history.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent earnings momentum, and relative positioning, Tickeron's AI would currently lean toward MDT as the more favorably positioned of the two. The stock's consecutive beats, upward guidance revisions, and improving analyst sentiment suggest a more stable and constructive trend, whereas ABT is contending with a revenue miss, segment-specific softness, and acquisition-related uncertainty. That said, the verdict is probabilistic rather than definitive: ABT retains a powerful device franchise and a potentially transformative diagnostics deal, meaning its setup could improve if Nutrition stabilizes and integration progresses. AI-driven analysis weighs current momentum and consistency, which presently appear stronger for MDT.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Hold and MDT is a Buy.
ABT in +2.49% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABT advanced for three days, in 172 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Oscillator exited the oversold zone, 19 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 51%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 28 of 54 cases over the following month. The odds of a continued upward trend are 52%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 54 cases where ABT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
The 10-day moving average for ABT crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.403) is normal, around the industry mean (2.923). P/E Ratio (32.423) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.025) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
MDT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for MDT moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 51 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 170 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 11 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
MDT broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MDT entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.369) is normal, around the industry mean (2.923). P/E Ratio (22.746) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.052). Dividend Yield (0.031) settles around the average of (0.009) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ABT | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 68 | 68 | |
PRICE GROWTH RATING 1..100 | 50 | 27 | |
P/E GROWTH RATING 1..100 | 4 | 56 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (39) in the Medical Specialties industry is in the same range as ABT (70). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
MDT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ABT (100). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
MDT's SMR Rating (68) in the Medical Specialties industry is in the same range as ABT (68). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
MDT's Price Growth Rating (27) in the Medical Specialties industry is in the same range as ABT (50). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
ABT's P/E Growth Rating (4) in the Medical Specialties industry is somewhat better than the same rating for MDT (56). This means that ABT’s stock grew somewhat faster than MDT’s over the last 12 months.
| ABT | MDT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 51% | 2 days ago 42% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 48% |
| Momentum ODDS (%) | 2 days ago 53% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 52% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 54% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 50% |
| Advances ODDS (%) | 7 days ago 56% | 8 days ago 54% |
| Declines ODDS (%) | 2 days ago 56% | 4 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 50% | 2 days ago 40% |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 46% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 1 FA rating(s) are green while MDT’s FA Score has 1 green FA rating(s).
- ABT’s FA Score: 1 green, 4 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 4 TA indicator(s) are bullish while MDT’s TA Score has 6 bullish TA indicator(s).
- ABT’s TA Score: 4 bullish, 5 bearish.
- MDT’s TA Score: 6 bullish, 5 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -1.79% price change this week, while MDT (@Medical/Nursing Services) price change was -1.27% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
Reported Earning Dates
ABT is expected to report earnings on Jan 27, 2027.
MDT is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.